Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States of 9,750,000 American Depositary Shares (ADSs) representing 9,750,000ordinary shares, at an initial public offering price of $18.00per ADS.